Background {#Sec1}
==========

Pulmonary cryptococcosis caused by *Cryptococcus neoformans C. Cryptococcus complexes* is very common in immunocompromised individuals, and it has become an emerging disease in immunocompetent ones \[[@CR1]--[@CR3]\]. Some reports have shown that pulmonary cryptococcosis occurs more frequently in immunocompetent patients than in immunocompromised ones \[[@CR4], [@CR5]\]. Compared with the current high incidence, the diagnosis of pulmonary cryptococcosis is still difficult because the clinical manifestations and imaging of pulmonary cryptococcosis have no obvious characteristics compared with other pulmonary diseases \[[@CR6]--[@CR8]\]. At present, diagnostic therapy and lung biopsy are mostly used to help diagnosis in China. But both methods have their drawbacks. Diagnostic using antifungal drugs have a long diagnosis cycle and side effects, and lung biopsy also has some indications, and it is invasive, difficult and complex to operate. Therefore, it is necessary to find a non-invasive and reliable method with few side effects. Some research \[[@CR9]--[@CR12]\] have shown that serum CrAg is a useful diagnostic methods. However, Serum CrAg detection negative is common among patients with Pulmonary cryptococcosis. Recent study \[[@CR13]\] has shown that serum CrAg is a useful diagnostic tool for pulmonary cryptococcosis in patients with extensive lung invasion. Based on that, we speculate that the radiological manifestations may affect the detection of serum CrAg. In addition, in a large number of clinical observations, we found that the immune status will also have an impact on their detection. (because the incidence of AIDS in China is relatively low, so it will not be discussed here.) Considering the above information, we want to figure out whether the pulmonary radiography and immune status could affect the CrAg detection.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

We retrospectively examined the hospitalized patients with pulmonary cryptococcosis between January 2012 and March 2019 in Zhujiang Hospital of Southern Medical University (Guangdong, China), Hospital of Southern Medical University (Guangdong, China) and Guangzhou People's Hospital (Guangdong, China). All patients' diagnoses were confirmed by percutaneous transthoracic needle biopsy (PTNB) or postoperative biopsy, and diagnosed by histopathological observations. Then, the data and information were collected: (1) demographic features and past medical history; (2) clinical features and symptoms; (3) laboratory tests, including white blood cell (WBC) counts, neutrophils counts, lymphocytes counts, concentrations of hemoglobin (Hb),platelet counts (PLT); (4) serum CrAg was detected by lateral flow assay (LFA) (IMMY, Norman, OK, USA); (5) chest radiological findings \[Fig. [1](#Fig1){ref-type="fig"}\]. Seventy-eight patients with pulmonary cryptococcosis were divided into two groups: the immunocompetent group and the immunocompromised group, according to whether they took immunosuppressive drugs or not. According to the detection of CrAg, each group was divided into the CrAg+ group and the CrAg- group. Then, according to Tao Zhu's research \[[@CR13]\], we define diffuse lesions as multiple lobes of the lung, multiple lesions of a single lobe, or lesions of a single lobe larger than 3 cm in diameter. Limited lesions are defined as lesions with a diameter of less than 3 cm in a single lobe. This study was approved by research Southern Pearl River Hospital Ethics Committee Medical University (No. 2016 HXNK 007), and all patients signed informed consents. Fig. 1Flow diagram of the study patient selection

Statistical analysis {#Sec4}
--------------------

Statistical analyses were performed with SPSS software, version 20.0. Continuous data are presented as the mean ± standard deviation or range. Chi-square test was used to analyze categorical variable. The independent t-test was obtained to analyze continuous variable. *P* \< 0.01 was considered statistically significant.

Results {#Sec5}
=======

Demographics and clinical data {#Sec6}
------------------------------

Patient demographic and clinical information is summarized in Table [1](#Tab1){ref-type="table"}. Our patients ranged in age from 15 to 81 years (mean age, 44.44 years). Forty-nine patients were male and 29 were female. Sixty-one patients had no immunodeficiency disorders, and 17 patients had received immunosuppressive therapy for a disease, 15 renal transplant patients received immunosuppressive therapy with cyclosporine, corticosteroids and mycophenolate. Two patients with acute leukemia received VP regimen (vincristine + prednisone) as chemotherapy regimen. Cough was the most common presenting symptom, occurring in 44 immunocompetent patients (72.13%) and 15 in immunocompromised patients (88.24%), followed by expectoration (55.74% vs 58.82%), chest pain (22.95% vs 23.53%), and fever (13.11% vs 17.65%). Nineteen people were asymptomatic,17 of whom had no immunodeficiency disease. There was no significant difference in the levels of WBC, neutrophils, lymphocytes, Hb and PLT between two groups (Table [2](#Tab2){ref-type="table"}). Table 1Medical history of patients with pulmonary cryptococcosisCharacteristicsImmunocompetent groupImmunocompromised groupPn6117Male(%)38(62.0)11(64.0)0.86^c^Age44.8243.060.65^t^Asymptomatic (%)17(27.87)2(11.76)0.29^c^Cough(%)44(72.13)15(88.24)0.29^c^expectoration (%)34(55.74)10(58.82)0.82^c^Chest pain (%)14(22.95)4(23.53)1.00^c^Fever (%)8(13.11)3(17.65)0.94^c^Underlying diseases (%)2(0.03)17(100)Hypertension20Kidney transplantation015Leukemia02^c^Chi-square test; ^t^t-test Table 2Laboratory investigations of patients with pulmonary cryptococcosisCharacteristicsImmunocompetent groupImmunocompromised groupPWBC (10^9^/L)7.27 ± 1.967.93 ± 2.570.26^t^Neutrophils4.87 ± 1.925.83 ± 1.940.07^t^Lymphocytes1.89 ± 0.571.75 ± 0.380.66^t^Hb(g/L)131.00 ± 17.87121.70 ± 23.470.08^t^PLT (10^9^/L)291.98 ± 107.67258.41 ± 116.670.26^tc^Chi-square test; ^t^t-test. *WBC* White blood cell; *Hb* Hemoglobin

Serum cryptococcal antigen and immune status {#Sec7}
--------------------------------------------

By comparing the results of cryptococcal antigen test in two groups, we found that the number of CrAg+ cases in the immunocompetent group was more than that in the immunocompromised group (49 vs 5), which was a significant statistical difference between the two groups (*P* \< 0.01). (Table [3](#Tab3){ref-type="table"}). Table 3Comparison of Cryptococcal Antigen Detection in the Immunocompetent and Immunocompromised groupCrAg expressionImmunocompetent groupImmunocompromised groupPCrAg+4950.0001^a^CrAg-1212^a^significant at 99% CI; *CrAg* Cryptococcal antigen

Chest radiology {#Sec8}
---------------

Table [4](#Tab4){ref-type="table"} showed that diffuse extent lesion was more common in CrAg+ group and limited extent lesion was more frequently observed in CrAg- group among the immunocompetent group (47 vs 7)(P \< 0.01). On the contrary, in the immunocompromised group, more diffuse lesions were found in the CrAg- group than in the CrAg+ group (10 vs 4)(*P* \> 0.01), as shown in Table [5](#Tab5){ref-type="table"}. Chest radiology and biopsy results in patients with pulmonary cryptococcosis were shown in Fig. [2](#Fig2){ref-type="fig"}. Table 4Comparison of Cryptococcal Antigen Detection and Radiography in the Immunocompetent groupCharacteristicsCrAg+CrAg-PDiffuse extent lesion4770.002^a^Limited extent lesion25^a^significant at 99% CI; *CrAg* Cryptococcal antigen Table 5Comparison of Cryptococcal Antigen Detection and Radiography in the Immunocompromised groupCharacteristicsCrAg+CrAg-PDiffuse extent lesion4101^a^Limited extent lesion12^a^significant at 99% CI; *CrAg* Cryptococcal antigen Fig. 2The chest radiological findings and biopsy results in patients with pulmonary cryptococcosis. (**a**) lesion (the diameter \< 3 cm) in a single lobe (limited extent lesion). (**b**) lesions in multiple lobes (diffuse extent); Lesion (black arrows). Biopsy results (**c-d),** Cryptococcus sp. yeasts (black arrows)

Treatment {#Sec9}
---------

There were 12 patients who received surgical resection, 5 patients who received surgery combined with antifungal drugs, 58 patients who received Antifungal monotherapy (56 cases were treated with fluconazole, 2 cases were treated with amphotericin), and 3 patients who were confirmed by biopsy were discharged from the hospital without treatment. (Table [6](#Tab6){ref-type="table"}). Table 6Comparison of treatment in the Immunocompetent and Immunocompromised groupCharacteristicsNOperationFluconazole monotherapyOperation combined with fluconazoleAmphotericin monotherapyOtherImmunocompetent group611034800Immunocompromised group1722823

Prognosis {#Sec10}
---------

The follow-up data of 23 patients were complete. In the immunocompetent group, all lesions were removed by operation in four patients and no recurrence was found in follow-up for several months. And 15 patients were treated with fluconazole alone. After treatment, it was found that all lesions were absorbed. In the immunocompromised group, 2 patients were treated with surgery combined with fluconazole, 1 patient was treated with fluconazole initially, and then was treated with amphotericin and sequential voriconazole. Lesions were cleared in all 3 patients. And all of them were limited extent lesion.

Discussion {#Sec11}
==========

In this study, a retrospective research of 78 patients with pulmonary cryptococcosis was conducted to investigate whether the patient's immune status and radiography affect the detection of cryptococcal antigen. Firstly, according to the patient's immune status, we divided these pulmonary cryptococcosis patients diagnosed by lung biopsy into the immunocompetent group and the immunocompromised group. We found the number of CrAg+ cases in the immunocompetent group was more than that in the immunocompromised group. This may indicate that the positive detection of serum cryptococcal antigen in immunocompetent individuals is more likely to represent the infection of pulmonary cryptococcosis. Moreover, in the immunocompetent group, diffuse lesions were more common in CrAg+ group and limited lesions were more frequently observed in CrAg- group. It suggests that the possibility of pulmonary cryptococcal infection is high, when immunocompetent patients with diffuse lung lesions have a positive serum cryptococcal antigen test. It has been reported that the detection of serum cryptococcal antigen is often negative in patients who have isolated pulmonary, and the presence of a positive serum cryptococcal antigen means the high possibility of deep tissue infiltration and disseminated diseases, \[[@CR14]--[@CR16]\]. But the result in the immunocompromised group was contrary (*p* \> 0.01), which may be related to the small sample size. The radiological findings of patients with pulmonary cryptococcosis are non-specific, and depend on the immune status of patients. In immunocompetent patients, solitary or multiple pulmonary nodules are common, while in immunocompromised patients, cavities often appear \[[@CR15], [@CR17]\]. Our findings in immunocompetent individuals have expanded the value of serum CrAg in the diagnosis of diffuse lesion in immunocompetent patients, supporting the results of previous studies that the most common CT findings of pulmonary cryptococcosis was multiple pulmonary nodules/masses of different diameters \[[@CR18]--[@CR21]\].

Similar to previous reports, our study also found that the most common symptoms of pulmonary cryptococcosis patients included cough and sputum, \[[@CR5], [@CR22]--[@CR24]\] with no significant specificity(Table [1](#Tab1){ref-type="table"}). Our laboratory examinations, including leucocyte, neutrophil, lymphocyte, Hb and PLT levels, showed no significant difference between immunocompetent and immunodeficient groups (Table [2](#Tab2){ref-type="table"}). This may confirm that cryptococcosis can inhibit the aggregation of pulmonary neutrophils and the production of inflammatory cytokines in immunocompetent host, thus affecting the immune function of healthy subjects \[[@CR23], [@CR25]\].

In conclusion, patient's immune status and CT manifestations would affect the detection of serum cryptococcal antigen. Serum CrAg could become a useful tool for the diagnosis of pulmonary cryptococcosis in immunocompetent patients with extensive lung involvement.

Future work {#Sec12}
-----------

Of course, there are some limitations. First of all, this is a retrospective study. We collected a relatively small number of cases, so we will expand the sample size and a series of cohort studies will be conducted next. And as pulmonary physicians, our research is limited to pulmonary cryptococcosis. In the future, we will strengthen cooperation with other departments and hospitals to deepen our understanding of cryptococcal and serum cryptococcal antigen detection. Finally, because of the incomplete data, we have not classified the pathogenic bacteria of cryptococcosis. From now on, we will continue to study whether the infection of specific Cryptococcus is related to the immune status of patients, CT findings and cryptococcal antigen detection.
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